Nasal Administration

Abstract

A delivery device for and method of providing for delivery of substance to the central nervous system (CNS) of a subject, the delivery device comprising: a nosepiece unit for insertion into a nasal airway of a subject and comprising an outlet unit which includes a nozzle for delivering substance into the nasal airway of the subject; and a substance supply unit which is operable to deliver a dose of substance to the nozzle; wherein the delivery device is configured such that at least 30% of the dose as initially deposited in the nasal airway is deposited in an upper posterior region of the nasal airway, thereby providing a CNS concentration of the substance, and hence CNS effect, which is significantly greater than that which would be predicted from a counterpart blood plasma concentration of the substance.

1 - 14 . (canceled) 
     
     
         15 . A method of treating migraine in a subject, comprising:
 fitting a mouthpiece to a mouth of the subject;   fitting a nosepiece unit to a first nostril of the subject, wherein the nosepiece unit comprises a nozzle, a delivery channel fluidly connected to the mouthpiece, and a substance supply unit containing a powdered sumatriptan substance;   causing exhalation breath of the subject through the mouthpiece to cause closure of the oropharyngeal velum of the subject and produce a bi-directional flow into one nasal passageway of the subject and out of the other nasal passageway of the subject;   delivering a dose of the powdered sumatriptan substance from the substance supply unit to the nasal airway of the subject through the nozzle when the exhalation flow reaches the predetermined flow rate;   depositing at least 30% of a dose of the powdered sumatriptan substance, as initially deposited in the nasal airway of the subject, to an upper posterior region of the nasal airway of the subject, which is posterior of a nasal valve of the subject and above an inferior meatus of the subject; and   providing a higher local concentration in a cerebrovasculature of the subject and a central nervous system (CNS) effect which is greater than that predicted from a counterpart blood plasma concentration of sumatriptan achieved using intravenous (IV) delivery.   
     
     
         16 . The method of  claim 15 , wherein at least 40% of the dose as initially deposited in the nasal airway is deposited in the upper posterior region of the nasal airway. 
     
     
         17 . The method of  claim 15 , wherein at least 50% of the dose as initially deposited in the nasal airway is deposited in the upper posterior region of the nasal airway. 
     
     
         18 . The method of  claim 15 , wherein the ratio of the peak CNS effect to the peak blood plasma concentration is at least 2 times that achieved using intravenous (IV) delivery. 
     
     
         19 . The method of  claim 15 , wherein the ratio of the peak CNS effect to the peak blood plasma concentration is at least 3 times that achieved using intravenous (IV) delivery.